Advice
In the absence of a submission from the holder of the marketing authorisation.
infliximab (Remicade) is not recommended for use within NHSScotland for the treatment of moderately to severely active ulcerative colitis in patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine or azathioprine, or who are intolerant to or have medical contraindications for such therapies.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice24KB (PDF)
Medicine details
- Medicine name:
- infliximab (Remicade)
- SMC ID:
- 374/07
- Indication:
- moderately to severely active ulcerative colitis.
- Pharmaceutical company
- Schering-Plough Ltd
- BNF chapter
- Gastro-intestinal system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 07 May 2007